To support the rapid growth of its clinic network, Novamind opened a dedicated call centre specialized in insurance benefit verification and prior authorizations. I look forward to further informing these decisions by soon publishing the results of real-world evidence studies and hosting upcoming clinical trials examining the use of psychedelic-assisted psychotherapy.”įor many medical and prescription drug plans, prior authorizations from insurance companies are required in advance of administering certain treatments-including IV ketamine for depression. “For ketamine therapy to reach the masses, many more insurance companies will need to adjust their coverage policies. Reid Robison, Novamind’s Chief Medical Officer. “This initial success with insurance coverage of ketamine is promising for the future of psychiatry because it sends a strong signal that payors are interested in more effective treatments for mental health conditions as supporting research emerges,” said Dr. Preliminary evidence suggests that when ketamine intervention is enhanced with therapeutic support, it may produce enduring benefits across a range of mental health disorders.1 While most insurance companies cover psychotherapy portions of this treatment, when used “off label” for psychiatric disorders, coverage for ketamine has typically been less common. Novamind administers ketamine in conjunction with psychotherapy, also known as ketamine-assisted psychotherapy. Ketamine has been safely used as an FDA approved anesthetic since 1970 and has found use in psychiatry to treat conditions including TRD. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has obtained approval for direct billing of intravenous (IV) ketamine for treatment-resistant depression (TRD) from four major health insurance providers: Blue Cross Blue Shield, the University of Utah, PEHP Health & Benefits and MBA Benefit Administrators. TORONTO, ON / ACCESSWIRE / Novem/ Novamind Inc. Novamind Secures Insurance Coverage for Ketamine from Four Major Payors Blue Cross added to list of insurance companies covering IV ketamine treatments at Novamind See below for a look at the complete press release: Having psychedelic therapy accepted by insurers is a major potential bottleneck for widespread acceptance and greater access, so headlines like this one are important stepping stones on the path forward. If Ketamine clinics can continue to prove themselves as viable commercial endeavors, and if Ketamine companies can continue to lay the groundwork for acceptance of psychedelics by insurance providers, then future psychedelic compounds will have an easier time navigating the difficult early years of regulatory approval. ![]() Ketamine is a real-world test case for the future of legal psychedelic therapy, so this bit of relatively un-sexy news has implications beyond the ketamine space. Ketamine has its own potential benefits for a variety of conditions, so acceptance by the insurance industry is an important piece of progress for those looking to gain access to mental health treatments. ![]() Novamind is a company that “provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research” - and they’ve announced that Blue Cross and other insurers were added to a list of insurance companies covering ketamine treatments at their facilities.Ĭurrently the only legal psychedelic drug being prescribed in North America, ketamine treatments are growing across the continent, with networks of treatments expanding across the continent. Slipping under the radar last week was an announcement that could have major implications for the future of the psychedelic medicine industry.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |